- Seattle Genetics (NASDAQ:SGEN): Q2 GAAP EPS of -$0.47 beats by $0.13.
- Revenue of $388.5M (+39.7% Y/Y) beats by $30.8M.
- 2021 Guidance: Re-affirmed ADCETRIS sales of $675M-$700M vs. $658.6M in FY20; Re-affirmed PADCEV sales of $310M-$325M vs. $222.4 in FY20; Re-affirmed TUKYSA sales of $300M-$315M vs. $119.6M in FY20; Re-affirmed royalty revenues of $125M-$135M vs. $126.7M in FY20.
- Press Release